Mysoline (Primidone)

Primidone is converted in the liver to phenobarbital, which enhances the activity of the inhibitory neurotransmitter GABA. By increasing GABA‑mediated neuronal inhibition, primidone lowers neuronal excitability, thereby decreasing the likelihood of seizure generation and spread.

The appropriate dose of Mysoline is determined individually by a prescribing healthcare professional based on the patient’s age, weight, seizure type, and response to therapy. Dosage adjustments are made according to clinical response and tolerability.

The safety of primidone during pregnancy or lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Mysoline.

To request Mysoline, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mysoline (primidone) is a barbiturate‑derived antiepileptic, similar in action to phenobarbital but often preferred for its dual metabolism. Compared with newer agents such as levetiracetam, primidone may have a broader side‑effect profile but remains effective for certain seizure types, especially generalized tonic‑clonic seizures.

Mysoline should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Mysoline is taken orally, usually as a tablet, with or without food as directed by a healthcare provider. The exact administration schedule, including timing and frequency, is individualized based on the patient’s therapeutic needs.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, blood disorders like agranulocytosis, and respiratory depression, especially when combined with other central nervous system depressants. Patients should seek immediate medical attention if they notice rash, fever, unexplained bruising, or breathing difficulties.

Mysoline is contraindicated in individuals with known hypersensitivity to primidone, phenobarbital, or any barbiturate components. It should also be avoided in patients with severe hepatic impairment or those taking interacting medications that could cause dangerous CNS depression.